Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

Bijal D. Shah, MD
Published: Thursday, Nov 09, 2017



Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.

Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
 


Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.

Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell TumorsApr 28, 20181.0
Publication Bottom Border
Border Publication
x